undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc key statistics and ratios

In fiscal 2026, Aytu Biopharma, Inc had return on equity of -52.6% and a net margin of -24.8%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Net margin<−999%<−999%<−999%−698.7%−278.3%−370.6%−49.3%−88.8%−112.5%−15.9%−24.3%−20.4%−24.8%
Return on equity−103.9%−73.6%——−116.9%—−26.7%−50.1%−119.6%−40.8%−47.2%−58.1%−52.6%
Return on assets−46.4%−51.1%−132.5%−114.4%−56.5%−97.3%−14.5%−27.8%−53.9%−12.4%−12.4%−11.2%−12.4%
R&D as % of revenue>999%>999%239.1%29.8%4.6%8.0%6.2%8.6%13.1%3.8%4.2%2.0%0.0%
SG&A as % of revenue—>999%332.4%541.4%484.5%258.0%125.9%——————

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $105m
Short-term assets $62mLonger-term assets $43m
What it owes, and who funded it · $90m
Short-term liabilities $55mShareholders' equity $35m
  • Short-term assets cover short-term liabilities $62m of assets due within a year against $55m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $26m of cash against $11m of debt.
  • Debt below 40% of shareholders' equity Debt is 31% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 31% over five years.
  • A year's operating cash flow covers at least 20% of debt $3m of operating cash flow against $11m of debt.
  • Operating profit covers interest at least five times over Operating income of −$8m against $2m of interest.

From Aytu Biopharma, Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

27 /100

Weak moat

How hard Aytu Biopharma's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.8% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 63.0%, moving by 10.0 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -83.1%; its worst year was -624.7%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 6 years, at a median -116.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AQST vs AYTUAYTU vs DERMAYTU vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aytu Biopharma, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aytu Biopharma, Inc.